Tourmaline Bio, Inc.
TRML · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -3.97 | -1.22 | -0.57 | -0.56 |
| FCF Yield | -4.92% | -5.55% | -3.99% | -3.54% |
| EV / EBITDA | -14.65 | -13.56 | -19.08 | -25.70 |
| Quality | ||||
| ROIC | -10.02% | -9.36% | -8.59% | -7.60% |
| Gross Margin | 0.00% | 0.00% | 50.00% | 0.00% |
| Cash Conversion Ratio | 0.88 | 0.94 | 0.94 | 1.16 |
| Growth | ||||
| Revenue 3-Year CAGR | 341,895.19% | 341,895.19% | 341,895.19% | 1,315,298.73% |
| Free Cash Flow Growth | 6.53% | -3.78% | 10.86% | -30.19% |
| Safety | ||||
| Net Debt / EBITDA | 1.20 | 1.34 | 1.17 | 1.42 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -16,762.50 | -16,123.50 | -18,486.00 |